公开(公告)号：EP3064221A1

公开(公告)日：2016-09-07

申请号：EP16165526.1

申请日：2013-04-16

申请人： Baxalta GmbH ,  Baxalta Incorporated

发明人： Kerschbaumer, Randolf ,  Scheiflinger, Friedrich ,  Ehrlich, Hartmut

IPC分类号： A61K39/395 ,  C07K16/24 ,  A61K31/7068 ,  A61K31/704 ,  A61K33/24 ,  A61K31/137 ,  A61P35/00 ,  A61K31/136 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K31/136 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/24 ,  C07K2317/21 ,  C07K2317/76 ,  A61K2300/00

摘要： The present invention pertains to anti-MIF antibodies, in particular their use in combination with cancer therapeutics, i.e. chemotherapeutics, in the treatment of cancer.

摘要翻译： 本发明涉及抗MIF抗体，特别是其与癌症治疗剂（即化学治疗剂）组合用于癌症治疗中的用途。

公开(公告)号：EP3045467A1

公开(公告)日：2016-07-20

申请号：EP16158434.7

申请日：2011-12-09

申请人： Baxalta GmbH ,  Baxalta Incorporated

发明人： Wauters, Cary ,  Zaydenberg, Alexander

IPC分类号： C07K1/14

CPC分类号： C07K1/30 ,  C07K1/24 ,  C07K1/303 ,  C07K1/34 ,  G01N27/021 ,  G01R27/00 ,  Y10T436/115831 ,  Y10T436/12 ,  Y10T436/25375

摘要： Methods and systems for monitoring and/or controlling protein separation, purification, extraction, and/or fractionation processes are provided. The impedance of a protein mixture undergoing a protein process is measured and compared to a target reference impedance value or range of reference impedance values. If the measured impedance is not within an acceptable deviation of the target reference impedance value, a parameter of the protein mixture or process is adjusted.

摘要翻译： 提供这样的方法和用于监测和/或控制蛋白的分离，纯化，提取系统和/或分馏过程。 蛋白质混合物经历蛋白过程的阻抗被测量并与目标参考阻抗值或范围的参考阻抗值。 如果测得的阻抗不内接受的目标参考阻抗值的偏差，所述蛋白质混合物或过程的参数进行调整。

公开(公告)号：EP2968456A1

公开(公告)日：2016-01-20

申请号：EP14720399.6

申请日：2014-03-14

申请人： Baxalta Incorporated ,  Baxalta GmbH

发明人： BAIRSTOW, Shawn, F. ,  RAMACHANDRAN, Sindhu ,  JOHNSON, Richard ,  SCHILL, Nicholas, J.

IPC分类号： A61K38/17 ,  A61P13/12 ,  A61P37/00 ,  A61P27/02

CPC分类号： C07K14/473 ,  A61K38/1709

摘要： Among other aspects, the present disclosure provides methods for preparing enriched compositions of plasma-derived Factor H from fractions formed during the manufacturing processes of established plasma-derived therapeutic compositions. Specifically, methods are provided for the isolation of Factor H from Fraction precipitates commonly discarded during the manufacture of commercial IgG therapeutics. Advantageously, the Factor H compositions prepared according to these methods have improved proteolytic profiles and reduced amidolytic activity.

公开(公告)号：EP2968455A2

公开(公告)日：2016-01-20

申请号：EP14718870.0

申请日：2014-03-14

申请人： Baxalta Incorporated ,  Baxalta GmbH ,  Madlener, Ruth ,  Schwarz, Hans-Peter ,  Svatos, Sonja ,  Teschner, Wolfgang ,  Pljevljakovic, Azra ,  Nitsch, Lena

发明人： MADLENER, Ruth ,  SCHWARZ, Hans-Peter ,  SVATOS, Sonja ,  TESCHNER, Wolfgang ,  PLJEVLJAKOVIC, Azra ,  NITSCH, Lena

IPC分类号： A61K38/17 ,  A61P13/12 ,  A61P27/02 ,  A61P37/00

CPC分类号： C07K14/47 ,  A61K35/16 ,  A61K38/1725

摘要： The present disclosure provides, among other aspects, improved methods for the manufacture of Factor H compositions from plasma precipitation fractions. In some aspects, the methods include an improved process step for extracting Factor H from a plasma precipitate fraction with reduced co-extraction of amidolytic activities. In other aspects, the methods include a heat treatment step for reducing impurities, such as amidolytic enzymes, from a Factor H composition. In yet other aspects, the methods include improved anion exchange, heparin affinity, and/or mixed mode chromatographic enrichment of Factor H. In still other aspects, the improved methods include a combination of the individual improved process steps disclosed herein.

公开(公告)号：EP2961426A1

公开(公告)日：2016-01-06

申请号：EP14714815.9

申请日：2014-02-25

申请人： Baxter International Inc ,  Baxalta GmbH ,  Baxalta Incorporated

发明人： FREY, William, H. ,  HANSON, Leah Ranae, Bresin ,  POKROPINSKI, Sharon ,  RAUSA, Francisco, M., III

IPC分类号： A61K39/395 ,  A61K9/00

摘要： The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.

摘要翻译： 本发明提供了，除其它方面，方法和组合物用于治疗中枢神经系统通过向脑通过该组合物的鼻内施用直接递送治疗有效量的合并的人免疫球蛋白G（IgG）的组合物的以（CNS）紊乱 鼻腔的嗅觉上皮。 特别是提供用于治疗阿尔茨海默氏病的方法和组合物。

公开(公告)号：EP2467399B1

公开(公告)日：2015-11-11

申请号：EP10747134.4

申请日：2010-08-20

申请人： Baxalta Incorporated ,  Baxalta GmbH

发明人： MITTERER, Artur ,  HASSLACHER, Meinhard ,  MAYER, Christa

IPC分类号： C07K14/755

CPC分类号： C07K14/755 ,  A61K38/00 ,  C07K1/18

公开(公告)号：EP2710377B8

公开(公告)日：2015-10-28

申请号：EP12725948.9

申请日：2012-05-18

申请人： Baxalta Incorporated ,  Baxalta GmbH

发明人： FERRARI, Silvia ,  GRUBER, Bernadette ,  PLAIMAUER, Barbara ,  ROTTENSTEINER, Hanspeter ,  SCHEIFLINGER, Friedrich

IPC分类号： G01N33/564

CPC分类号： G01N33/564

公开(公告)号：EP4039249A1

公开(公告)日：2022-08-10

申请号：EP22164436.2

申请日：2011-05-26

申请人： Baxalta GmbH ,  Baxalta Incorporated

发明人： Teschner, Wolfgang ,  Schwarz, Hans-Peter ,  Madlener, Ruth ,  Svatos, Sonja ,  Pljevljakovic, Azra ,  Weber, Alfred

IPC分类号： A61K9/08 ,  A61K47/18 ,  A61K9/00 ,  A61K38/17 ,  C07K16/00 ,  A61K35/16 ,  A61P7/00 ,  A61P13/12 ,  A61P27/02 ,  A61P31/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  C07K1/30 ,  C07K1/36 ,  C07K16/06

摘要： The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and/or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

公开(公告)号：EP3708581A1

公开(公告)日：2020-09-16

申请号：EP19198667.8

申请日：2010-05-27

申请人： Baxalta GmbH ,  Baxalta Incorporated

发明人： Teschner, Wolfgang, Dr. ,  Butterweck, Harald Arno ,  Pljevljakovic, Azra ,  Bauer, Theresa Friederike ,  Koelbl, Bernhard ,  Schwarz, Hans-Peter ,  Nikolic, Nebojsa ,  Poelsler, Gerhard ,  Kindermann, Johanna

IPC分类号： C07K16/06 ,  B01D61/14

摘要： The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.

公开(公告)号：EP3682897A1

公开(公告)日：2020-07-22

申请号：EP19211162.3

申请日：2013-07-11

申请人： Baxalta GmbH ,  Baxalta Incorporated

发明人： Barrett, Noel P. ,  Aichinger, Gerald ,  Crowe, Brian A. ,  Livey, Ian ,  Wressnigg, Nina

IPC分类号： A61K39/02 ,  C07K16/12 ,  A61P31/04

摘要： The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.